Related Experiment Video
Updated: Dec 7, 2025
09:36
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
2.5K
Enteral Bioactive Factor Supplementation in Preterm Infants: A Systematic Review
Elise Mank1, Eva F G Naninck1,2, Jacqueline Limpens3
1Department of Pediatrics-Neonatology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Vrije Universiteit, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Nutrients
|September 29, 2020
Summary
Supplementing preterm infant nutrition with bioactive factors shows promise for reducing complications. However, more high-quality research is needed before widespread clinical use, with ongoing trials on insulin and vitamin A potentially offering clearer answers.
Area of Science:
- Neonatal nutrition
- Human milk bioactive factors
- Clinical trial research
Background:
- Mother's own milk improves outcomes for preterm infants.
- Human milk bioactive factors are explored for nutritional supplements.
- Previous reviews excluded lactoferrin, vitamin D, K, and iron.
Purpose of the Study:
- To review bioactive factors used as supplements in preterm infant enteral nutrition.
- To overview ongoing clinical trials on these supplements.
Main Methods:
- Systematic review of randomized controlled trials.
- Searches conducted in MEDLINE, EMBASE, CENTRAL, and clinical trial registers.
- Exclusion of studies on lactoferrin, vitamins D, K, and iron.
Main Results:
- 17 different bioactive factors were identified across 26 studies.
- Several factors showed encouraging potential effects.
- Three large ongoing trials (n > 500) are investigating enteral insulin and vitamin A.
Conclusions:
- More high-quality studies are necessary before implementing specific bioactive factors into clinical practice.
- Ongoing trials on enteral insulin and vitamin A may provide definitive answers.
Related Concept Videos
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
165
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
165
01:22Bioavailability: Influencing Factors
217
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
217
01:23Factors Influencing Bioavailability: First-Pass Elimination
7.6K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
7.6K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
144
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
144
01:13Bioavailability: Overview
3.7K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.7K
01:17Bioavailability: Overview
195
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
195